Equillium (NASDAQ:EQ) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Equillium (NASDAQ:EQ) announced its quarterly earnings data on Thursday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06, Zacks reports. The firm had revenue of $4.39 million during the quarter. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%.

Equillium Trading Down 16.0 %

Shares of EQ stock traded down $0.08 during trading hours on Friday, hitting $0.41. The company’s stock had a trading volume of 214,635 shares, compared to its average volume of 360,226. The company has a 50 day moving average of $0.76 and a 200 day moving average of $0.80. The stock has a market cap of $14.53 million, a PE ratio of -2.90 and a beta of 1.87. Equillium has a 12-month low of $0.39 and a 12-month high of $2.45.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners reissued a “market perform” rating and set a $1.00 price objective (down from $3.00) on shares of Equillium in a report on Friday.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.